Memantine is Superior to Donepezil for Dementia-Related Behavioral Disturbances
For dementia-related behavioral disturbances specifically, memantine demonstrates superior efficacy compared to donepezil (a cholinesterase inhibitor), with the strongest evidence supporting combination therapy of memantine plus donepezil for optimal behavioral symptom control.
Evidence for Behavioral Symptom Management
Memantine's Specific Benefits for Behavior
The guideline evidence consistently shows that memantine has a protective effect against agitation and improves behavioral disturbances 1. Specifically:
- In most memantine studies, agitation was less frequently reported in the treatment group than in the placebo group 1
- The summary estimate showed significant effect size for the Neuropsychiatric Inventory in patients with Alzheimer disease 1
- One study demonstrated improvements in the Neuropsychiatric Inventory caregiver distress subscale 1
Cholinesterase Inhibitors Show Limited Behavioral Benefits
In contrast, the guideline evidence for cholinesterase inhibitors (including donepezil) is far less compelling for behavioral symptoms:
- Reviews noted only small changes in neuropsychiatric symptoms with cholinesterase inhibitors 1
- The evidence for behavioral improvement with donepezil monotherapy is not consistently demonstrated 1
The Combination Therapy Advantage
The most robust evidence supports using memantine combined with donepezil for behavioral disturbances 2, 3, 4:
- A landmark 2004 RCT showed that adding memantine to stable donepezil therapy produced significant improvements on the Neuropsychiatric Inventory compared to donepezil alone 2
- Recent meta-analyses confirm that combination therapy is superior for neuropsychiatric symptoms (MD -6.84,95% CrI -10.62 to -2.82) compared with placebo 3
- The 2025 real-world cohort study demonstrated that combination therapy (AChEI + memantine) stabilized cognitive function and reduced mortality by 39% in severe dementia 5
Clinical Algorithm for Behavioral Disturbances in Dementia
Step 1: If the patient is on donepezil monotherapy and experiencing behavioral disturbances → Add memantine 20 mg/day (titrate from 5 mg/day weekly)
Step 2: If the patient is treatment-naïve with prominent behavioral symptoms → Initiate memantine monotherapy rather than donepezil, as memantine shows protective effects against agitation 1
Step 3: For moderate-to-severe dementia with behavioral disturbances → Use combination therapy from the outset (memantine + donepezil), as this provides the most comprehensive benefit 2, 4, 6
Safety Considerations
Memantine has superior tolerability for behavioral management:
- Withdrawal rates due to adverse events: 7-13% with memantine versus higher rates with cholinesterase inhibitors 1
- Memantine actually reduces agitation as an adverse event, unlike cholinesterase inhibitors which can worsen behavioral symptoms 1
- The FDA label confirms memantine is well-tolerated both as monotherapy and in combination with donepezil 7
Important Caveats
While memantine is superior for behavioral symptoms, recognize that:
- The effect sizes, while statistically significant, are modest - don't expect dramatic behavioral transformations 1
- Most trial durations were 24-28 weeks, so long-term behavioral benefits beyond 6 months are less well-established 1
- For vascular dementia specifically, memantine showed benefits on behavioral scales (Nurses Observation Scale for Geriatric Patients) 1
Bottom Line
Memantine outperforms donepezil for dementia-related behavioral disturbances, with combination therapy (memantine + donepezil) providing the optimal approach for both behavioral symptoms and overall disease management 8, 3, 6, 9. The 2025 guideline strongly recommends memantine for moderate-to-severe AD, noting its significant benefits on neuropsychiatric symptoms 6.